Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296026 | 0.91 | EPAS1 (0.41) | GAACTSLIDO1KDM4EDRD2 | |
| SCHEMBL1295749 | 0.86 | KCNQ3 (0.41) | GAACTSLIDO1KDM4E | |
| SCHEMBL1294547 | 0.86 | CTSL (0.52) | GAACTSLIDO1KDM4ESYK | |
| SCHEMBL1294872 | 0.85 | GAA (0.54) | GAAIDO1DRD2LMNAALDH1A1 | |
| SCHEMBL1296001 | 0.82 | GAA (0.41) | GAACTSLIDO1KDM4ESTS | |
| SCHEMBL1295998 | 0.82 | GAA (0.41) | GAACTSLIDO1KDM4ESTS | |
| SCHEMBL6349425 | 0.82 | CTSS (0.40) | GAAIDO1KDM4ASYKTDP1 | |
| SCHEMBL1295463 | 0.81 | EGFR (0.47) | GAAIDO1KDM4ELMNAALDH1A1 | |
| SCHEMBL1295139 | 0.81 | RIPK1 (0.37) | GAAIDO1KDM4ASYKTDP1 | |
| SCHEMBL1295492 | 0.81 | KDM4E (0.43) | GAAKDM4EKDM4ASYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2004166-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
| WO-2007120528-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120528-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | VCAM1, AOC3, AOC2 | GAA 1702/4885CTSL 2838/4885IDO1 447/4885 |
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOC3, AOC2 | GAA 1702/4885CTSL 2838/4885IDO1 447/4885 |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOC3, AOC2 | GAA 1702/4885CTSL 2838/4885IDO1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.